South China Morning Post
Hong Kong watchdog investigates Cloudbreak Pharma for ‘rigged’ IPO, suspends its shares
Hong Kong’s Securities and Futures Commission (SFC) has directed the stock exchange to suspend trading of US-based biotech firm Cloudbreak Pharma pending an investigation into its US$78 million initial public offering (IPO) last year. “The…
View original source — South China Morning Post ↗
Related stories
The Next Web
TechnologySep 4, 2026 · 1 min
Export controls went after China’s chips. They never touched the capital, and Moonshot is reportedly seeking $5bn.
The Next Web
Bloomberg
ScienceJun 5, 2026 · 1 min
Chinese, Hong Kong Investors Banned from SpaceX IPO
Bloomberg
Bloomberg
ScienceJun 5, 2026 · 1 min
Chinese, HK Investors Banned From SpaceX IPO on Security Grounds
Bloomberg
Bloomberg
BusinessSep 4, 2026 · 1 min
China’s Moonshot Said to Seek Up to $5 Billion in Hong Kong IPO This Year
Bloomberg